Drug Res (Stuttg) 2015; 65(S 01): S13
DOI: 10.1055/s-0035-1558063
Symposium der Paul-Martini-Stiftung
Georg Thieme Verlag KG Stuttgart · New York

Development of a Disease-Modifying OA Drug (DMOAD) in Knee Osteoarthritis: The Example of Sprifermin

K. Marhardt*
1  Merck Gesellschaft mbH, Vienna, Austria
N. Muurahainen*
2  EMD Serono, Rockland/MA, USA
› Author Affiliations
Further Information

Publication History

Publication Date:
04 November 2015 (online)

  1. Introduction: OA and unmet clinical need for a DMOAD

  2. Past DMOAD drug development

  3. Sprifermin, its MOA, and clinical development program

  4. Lessons learned, summary, and next steps

* both are affiliates of Merck KGaA, Darmstadt, Germany